Phase 2
N=172
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Bottom Line
View on ClinicalTrials.gov: NCT01606735 ↗Enrolled (actual)
172
Serious AEs
6.4%
Results posted
Sep 2014
Primary outcome: Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- IBI-10090 (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- ICON Bioscience Inc
- Primary completion
- Mar 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Anterior Chamber Cell Count at Day 8 Post-Treatment |
50; 51.8; 60.3 | — |
Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
Eligibility Criteria
Inclusion Criteria
- Patients scheduled for unilateral cataract surgery
Exclusion Criteria
- Ocular, topical, or oral corticosteroids within 7 days of Day 0
Data sourced from ClinicalTrials.gov (NCT01606735). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.